# Selectis Health, Inc. · Edgar & Edgarette company card

> Selectis Health grew revenue 4.9% in FY2025 to $41 million, operating margin -3.8% against a 24.7% median for real estate investment trusts, equity -19.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 727346 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/727346) · [JSON](https://www.pops4.com/boards/company/727346.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $41M |
| Revenue growth, 1 year | 4.9% |
| Revenue growth per year | 9.1% |
| Operating margin | -3.8% (prior year -6.9%) |
| Net margin | -2.5% |
| Operating cash flow | $2M |
| Capital spending | $443,611 |
| Free cash flow | $1M |
| Cash | $1M |
| Long-term debt | $31M |
| Total assets | $33M |
| Total equity | −$6M |
| Equity ÷ assets | -19.1% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Piotroski F: 7 of 9 (solid)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late annual report notice, late quarterly report notice in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); slow and jumpy: growing slower than its size class, with revenue that swings more; operating loss: a margin of -3.8% in FY2025; revenue is hard to predict: its 80% range is ±64%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $41.4M (FY2025), total debt $31.4M. Experience: revenue up 4.9% on the year, up 9.1% a year over 4 years; operating margin -3.8%, up from -6.9%. Soundness: equity -19.1% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $19.7M and $89.2M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $17.8M to $99.3M. A statistical range, not company guidance. Against peers (79 filers, $50M+ revenue, real estate investment trusts): operating margin -3.8% against a 24.7% median; growth 4.9% against 3.7%.

Range logged 2026-09-28, receipt 231f5aa522e451e3, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-03-31 ([filing](https://www.sec.gov/Archives/edgar/data/727346/000149315226014109/0001493152-26-014109-index.htm))
- Item NT 10-Q Late quarterly report notice: 2, latest 2026-08-18 ([filing](https://www.sec.gov/Archives/edgar/data/727346/000149315226038861/0001493152-26-038861-index.htm))
- Item 5.02 Director or officer change: 6, latest 2026-10-09 ([filing](https://www.sec.gov/Archives/edgar/data/727346/000149315226046568/0001493152-26-046568-index.htm))

## Recent filings

- 8-K · filed 2026-10-09 · 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation; 3.03 Material Modifications to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure or Election of Directors; Appointment of Officers; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/727346/000149315226046568/0001493152-26-046568-index.htm)
- 8-K · filed 2026-09-09 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.03 Material Modifications to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/727346/000149315226041840/0001493152-26-041840-index.htm)
- 10-Q · filed 2026-08-24 · [filing](https://www.sec.gov/Archives/edgar/data/727346/000149315226039909/0001493152-26-039909-index.htm)
- 8-K · filed 2026-06-24 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/727346/000149315226029837/0001493152-26-029837-index.htm)
- 10-Q · filed 2026-05-22 · [filing](https://www.sec.gov/Archives/edgar/data/727346/000149315226024987/0001493152-26-024987-index.htm)
- 8-K · filed 2026-05-20 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/727346/000149315226024584/0001493152-26-024584-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000727346.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=727346

## Cite

POPS4, Edgar & Edgarette: Selectis Health, Inc. company card, from the company's own SEC filings, accessed 2026-11-13, https://www.pops4.com/boards/company/727346. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.